Edit-R crRNA Library

Arrayed collections of predesigned synthetic crRNA for high-throughput screening across entire gene families for human and mouse.


Collections of algorithm-designed crRNAs targeting human and mouse gene families and pathways of interest are assembled in arrayed libraries for rapid loss-of-function studies.

CRISPR-Cas9 gene editing has emerged as a powerful tool for functional genomics studies. Edit-R crRNA libraries enable rapid, high-throughput analysis of hundreds of genes with multiple target sites per gene, including Human Druggable and Genome collections. As opposed to lentiviral pooled screening, this arrayed library format permits single-well analysis with nearly any phenotypic assay; including high-content assays and other morphological or reporter assays.

Please note that Edit-R synthetic tracrRNA is required for use with all synthetic crRNA products

Highlights of the Edit-R crRNA Libraries

  • Edit-R predesigned crRNA are selected by the Edit-R algorithm as highly functional and specific to their target sequences for robust, reliable gene knockout and chemically modified for improved nuclease resistance
  • Four unique crRNA designs per gene, provided as individuals or a pooled reagent, delivering robust gene knockout for high-confidence phenotypic results.
  • Conveniently arrayed in 96- or 384-well plates and offered as gene family collections. Echo-qualified 384-well plates are available upon request
  • Also available as crRNA cherry-pick libraries; simply upload your own gene list and customize your plate

If you're considering the purchase of a Druggable or Genome crRNA library, learn about how the Genomics Discovery Initiative can support your screening efforts!

Human Druggable is made up of: Proteases, Protein Kinases, Phosphatases, Transcription Factors, Ubiquitin Enzymes, GPCRs, Ion Channels and Drug Targets.

Human crRNA Libraries # genes (approximate) Catalog # (Pool/Set of 4)
Human Edit-R - Cell Cycle Regulation 169 GP/GC-003205-xx
Human Edit-R - Cytokine Receptors 110 GP/GC-004005-xx
Human Edit-R - Deubiquitinating Enzymes 94 GP/GC-004705-xx
Human Edit-R - DNA Damage Response 240 GP/GC-006005-xx
Human Edit-R - Drug Targets 3686 GP/GC-004650-xx
Human Edit-R - Druggable Genome 8422 GP/GC-004605-xx
Human Edit-R - Epigenetics 835 GP/GC-006105-xx
Human Edit-R - G Protein-coupled Receptors 390 GP/GC-003605-xx
Human Edit-R - Genome 19,127 GP/GC-005005-xx
Human Edit-R - Ion channels 417 GP/GC-003805-xx
Human Edit-R - Membrane Trafficking 140 GP/GC-005505-xx
Human Edit-R - Nuclear Receptors 52 GP/GC-003405-xx
Human Edit-R - Phosphatases 248 GP/GC-003705-xx
Human Edit-R - Proteases 527 GP/GC-005105-xx
Human Edit-R - Protein Kinases 746 GP/GC-003505-xx
Human Edit-R - Transcription Factors 1580 GP/GC-005805-xx
Human Edit-R - Tyrosine Kinases 90 GP/GC-003105-xx
Human Edit-R - Ubiquitin Enzymes 738 GP/GC-006205-xx
Mouse crRNA Libraries # genes (approximate) Catalog # (Pool/Set of 4)
Mouse Edit-R - Cell Cycle Regulation 105 GP/GC-013200-xx
Mouse Edit-R - Cytokine Receptors 139 GP/GC-014000-xx
Mouse Edit-R - Deubiquitinating Enzymes 100 GP/GC-014700-xx
Mouse Edit-R - Epigenetics 724 GP/GC-016100-xx
Mouse Edit-R - G Protein-coupled Receptors 515 GP/GC-013600-xx
Mouse Edit-R - Ion Channels 340 GP/GC-013800-xx
Mouse Edit-R - Membrane Trafficking 113 GP/GC-015505-xx
Mouse Edit-R - Nuclear Receptors 46 GP/GC-013400-xx
Mouse Edit-R - Phosphatases 273 GP/GC-013700-xx
Mouse Edit-R - Proteases 599 GP/GC-015100-xx
Mouse Edit-R - Protein Kinases 774 GP/GC-013500-xx
Mouse Edit-R - Transcription Factors 1419 GP/GC-015800-xx
Mouse Edit-R - Tyrosine Kinases 92 GP/GC-013105-xx
Mouse Edit-R - Ubiquitin Enzymes 752 GP/GC-016200-xx

 

  
HazardousNo
Shelf Life12 Months
Shipping ConditionAmbient
Stability at Recommended Storage ConditionsAt least 12 months
Storage Condition-20 C
mitotic-index-crRNA-graph.png

Increase of mitotic index upon knockout of PLK1 and KIF11 with synthetic crRNA:tracrRNA

mitotic-index-crRNA-graph.png

U2OS-(Ubi)EGFP-Cas9 stable cells seeded at 5,000 cells/well in 96-well format were transfected the following day with four different crRNA:tracrRNA complexes at 25 nM concentration targeting PLK1 and KIF11. Four non-targeting crRNA controls (NTC), cells transfected with lipid alone (Lipid) or left untreated (UT) were used as negative controls. Cells were fixed at 48 hrs post-transfection and stained with anti Phospho-Histone H3 antibody (DY550 secondary antibody) and Hoechst 33342. Cell images were analyzed on the IN Cell Analyzer 2200 imaging system (GE Healthcare) and percent cells positive for Phospho-Histone H3 (Mitotic Index, MI) was normalized to the average MI of the negative NTC crRNAs.


IF-cells-mitotic-index-crRNA.jpg

Increase of cells stained with mitotic marker upon PLK1 and KIF11 knockout by synthetic crRNA:tracrRNA

IF-cells-mitotic-index-crRNA.jpg

U2OS-(Ubi)EGFP-Cas9 stable cells were plated at 5,000 cells/well in 96-well format and transfected the next day with 25 nM crRNA:tracrRNA targeting PLK1 or KIF11. Non-targeting crRNA (NTC1) or cell treated with lipid alone were used as negative controls. Cells were fixed at 48 hours post-transfection and stained with anti-Phosho-Histone H3 (PH3) antibody (DY550 secondary antibody) and Hoechst 33342. Cell images were taken with IN Cell Analyzer 2200 imaging system (GE Healthcare). Fluorescent images presented with merged signal from nuclei (blue) and PH3 (red).


ApoOne_crRNA_graph.png

Knockout of essential genes by synthetic crRNA:tracrRNA results in apoptosis

ApoOne_crRNA_graph.png

U2OS-(Ubi)EGFP-Cas9 stable cell seeded at 10,000 cells/well in 96-well format were transfected the following day with four different crRNA:tracrRNA complexes at 25 nM concentration targeting PLK1, KIF11 or BCL2L1 or four non-targeting crRNA controls (NTC). Wells transfected with lipid alone (Lipid) or left untreated (UT) were also included as controls. The effects on apoptosis were assayed using Casp3/9 homogeneous assay (ApoONE, Promega) at 48 hours post-transfection. Data normalized to average of NTC (non-targeting) crRNA controls.


Brightfield_cell_death_knockout.jpg

Cell death phenotype observed following knockout of PLK1 and KIF11 with synthetic crRNA:tracrRNA

Brightfield_cell_death_knockout.jpg

U2OS-(Ubi)EGFP-Cas9 stable cell seeded at 10,000 cells/well in 96-well format were transfected the following day with four different crRNA:tracrRNA complexes targeting PLK1 and KIF11 at 25 nM concentration. Non-targeting crRNA #1 (NTC-1) or PPIB crRNA were used as negative controls. Bright filed images were taken at 48 hours post-transfection (20x, Leica DMIL microscope).


crrna-tracrna-screening-workflow-web.gif

Gene knockout workflow using Cas9-expressing cells with synthetic crRNA:tracrRNA

crrna-tracrna-screening-workflow-web.gif

For optimal results in a crRNA library workflow, it is recommended to establish stable expression of the Cas9 nuclease to improve knockout efficiency. Subsequent transfection of crRNA:tracrRNA is very straightforward and can be carried out in a high-throughput manner.